Back to News
Market Impact: 0.3
Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue Estimates
Source: zacks.com
Corporate EarningsAnalyst EstimatesCompany Fundamentals
Jazz Pharmaceuticals reported a quarterly loss of $3.88 per share, narrower than the Zacks consensus estimate of a $4.09 loss. That compares with earnings of $8.13 per share a year earlier.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
-0.10
Ticker Sentiment
JAZZ0.40
More News
- Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash